Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR ...
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
U.S. stock index futures rose on Friday after Apple forecast strong sales growth, while investors awaited key inflation data that could influence the Federal Reserve's policy decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback